Breast cancer screening looks for signs of disease before symptoms appear. Mammography can identify changes that need further evaluation, but a screening result alone does not establish a breast cancer diagnosis. Understanding that distinction helps explain both the value and the limitations of screening. NCI breast cancer screening
Screening mammograms and diagnostic evaluation
A screening mammogram is performed in someone without breast cancer symptoms as part of routine early-detection care. A diagnostic mammogram may be used after a symptom, abnormal screening result, or other concern has already been identified. Both use x-ray imaging, but they answer different questions.
An abnormal mammogram is not the same as a cancer diagnosis. Additional imaging may be needed, and when cancer is suspected, tissue sampling by biopsy is generally required to establish the diagnosis and provide material for pathology and biomarker testing. NCI: Mammograms
Who the USPSTF screening recommendation covers
The 2024 U.S. Preventive Services Task Force (USPSTF) recommendation calls for mammography every two years from ages 40 through 74 for women at average risk, including other people assigned female at birth covered by the statement. This is a U.S. recommendation for a defined population, not a universal schedule for every person. USPSTF breast cancer screening recommendation
The USPSTF found insufficient evidence to assess the balance of benefits and harms for screening at age 75 or older, or for supplemental ultrasound or MRI after a negative mammogram, including in people with dense breasts. An insufficient-evidence statement is not proof that an intervention has no benefit.
The recommendation does not apply to people with harmful BRCA1 or BRCA2 variants or other high-risk genetic syndromes, a history of high-dose chest radiation at a young age, previous breast cancer, or certain high-risk breast lesions. These circumstances require separate clinical assessment.
Benefits and limitations of breast cancer screening
Mammography can detect cancers before symptoms appear and reduces breast-cancer mortality at the population level. But screening also produces false-positive findings, additional imaging, biopsies that do not show cancer, and some overdiagnosis—detection of cancers that would not have caused harm during a person’s lifetime.
These tradeoffs do not make screening ineffective. They explain why screening recommendations specify a population and interval instead of claiming that more testing is always better.
How to interpret a screening recommendation
Screening is an early-detection process. Diagnosis is a separate process that evaluates a specific abnormality and may require biopsy. Biomarker testing comes later, after cancer tissue is available, to help characterize the disease and guide treatment planning.
When comparing trusted breast cancer information sources, check the organization, publication date, risk group, and question being answered. Screening identifies a possible signal; diagnostic evaluation determines what that signal means.
This article is intended for scientific education. Screening decisions should be made with a qualified health professional using guidance appropriate to the individual’s age, risk factors, history, and local clinical standards.
